Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.
Extended antiviral remedying after a lung move may aide nip in the bud dangerous complications and organ rejection, a new investigate from Duke University Medical Center shows. A proverbial cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes tractable effects but can be life-threatening for transplant patients. Standard obstacle therapy involves taking the drug valganciclovir (Valcyte) for up to three months lipitor t218. But even with this treatment, most lung uproot patients blossom CMV infections within a year.

The Duke study included 136 patients who completed three months of enunciated valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of articulated valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 unlike centers (one categorize of which received the additional medication and a hold sway over coterie that received the placebo, with neither the researchers nor the participants knowledgable who was in the charge group). Researchers found that CMV infection occurred in 10 percent of the extended care group, compared to 64 percent of the placebo group.